Key points
- โMulti-year follow-up studies of CBT for depression and anxiety find treatment gains substantially maintained, with relapse rates meaningfully lower than for medication-only treatment after discontinuation.
- โStudies comparing higher-dose and lower-dose CBT protocols with equivalent skill-building content find similar long-term outcomes, suggesting sessions help mainly insofar as they build transferable skills.
- โStructured relapse-prevention planning built into the final sessions of therapy roughly halves relapse rates in the following year compared to treatment that ends without one.
Most of what we know about whether therapy works comes from studies that measure outcomes right after treatment ends, or a few months later at most. That leaves an important question mostly unanswered in the popular conversation about therapy: does it last? A smaller but growing body of longitudinal research โ following people for years, not weeks โ gives a more complete, and more useful, answer.
The findings are broadly encouraging, though with real nuance about what predicts durability and what doesn't, and about which conditions and which kinds of therapy hold up best over years rather than months. Here's what tracking people well beyond the end of treatment actually shows, and why it matters for how a course of therapy should be structured in the first place.
What long-term actually means in this research
Most therapy outcome trials measure results at the end of treatment and, if researchers are being thorough, at a follow-up point three to twelve months later. True longitudinal studies โ tracking people for one to six years or longer โ are rarer, more expensive, and harder to conduct, since participants move, drop out of contact, or start other treatments in the meantime. The studies that do exist are correspondingly valuable, because they're answering a different and arguably more important question than most therapy research addresses.
Therapy versus medication, after you stop
One of the more consistent and clinically important findings in this literature is the comparison between what happens after therapy ends versus what happens after medication is discontinued. Multiple long-term follow-up studies of CBT for depression and anxiety find that treatment gains are substantially maintained over one to six years, with relapse rates meaningfully lower than for medication-only treatment after discontinuation. This doesn't mean medication doesn't work โ it works well for many people while being taken โ but the durability profile after stopping treatment differs in a way that matters for treatment planning.
Why therapy might outlast the treatment itself
One proposed explanation for the gap between therapy and medication durability is mechanistic: medication changes neurochemistry for as long as it's taken, while therapy aims to change how someone interprets and responds to their own thoughts and circumstances โ a change that, once learned, doesn't require ongoing input to persist, the way a skill like riding a bicycle doesn't disappear when practice stops. This is a plausible explanation rather than a fully proven one, but it fits the pattern seen across multiple follow-up studies.
Why skills seem to outlast sessions
A useful explanatory idea that's emerged from this research is that what predicts long-term maintenance isn't the total number of sessions attended, but whether someone actually acquired transferable skills during treatment โ the ability to notice a thinking pattern, interrupt an avoidance cycle, or regulate a stress response without a therapist present. Studies comparing higher-dose and lower-dose CBT protocols with equivalent skill-building content find similar long-term outcomes, which suggests more sessions help mainly insofar as they help someone actually learn and practice the skill.
The relapse-prevention plan matters more than people expect
Therapy protocols that explicitly build a relapse-prevention plan into the final sessions โ identifying early warning signs, rehearsing a specific response, and setting a plan for re-engaging support if needed โ show meaningfully better long-term outcomes than otherwise-similar treatment that ends without this step. Several comparative studies find relapse rates roughly halved in the following year for clients who received structured relapse-prevention planning, which has made it a fairly standard closing component of well-run CBT courses even though it takes only a session or two to complete.
Which conditions hold up best
Durability isn't uniform across diagnoses. Follow-up studies show the strongest long-term maintenance for anxiety disorders and mild to moderate depression treated with CBT, and somewhat weaker durability for recurrent, severe depression, where relapse is more common regardless of treatment type and ongoing management is often appropriate. This isn't a failure of therapy โ recurrent depression has a documented tendency to recur across treatment modalities โ but it does mean the expectation of durability should be calibrated to the specific presentation.
The dropout and attrition problem
It's worth being honest about a limitation that runs through most of this research: long-term follow-up studies lose participants over time, and the people who stay in contact with researchers for years may differ systematically from those who don't, potentially in ways that make outcomes look somewhat better than they'd be in a complete sample. Researchers use statistical methods to estimate and adjust for this, but it remains a genuine limitation worth keeping in view when interpreting any multi-year outcome study.
What happens when people top up
Longitudinal studies also track what happens to people who return for occasional booster sessions after finishing a full course of treatment, rather than either stopping completely or restarting therapy from scratch. The evidence suggests this middle path โ brief, infrequent check-ins rather than either extreme โ is associated with better maintained outcomes over multi-year follow-up than either fully discontinuing contact or defaulting back into open-ended weekly sessions, though the research on optimal booster frequency is still developing.
None of this is an argument that therapy is a one-time fix that should never be revisited. Life circumstances change, new stressors emerge, and returning to support when something new comes up is not evidence that the earlier treatment failed. The longitudinal data is better read as reassurance that the skills built in a well-run course of therapy are durable, real, and yours to keep.
This is part of why YouMindo is built around ongoing access rather than a fixed course that ends and disappears โ mood tracking, journaling, and exercises that stay available long after a course of therapy wraps up, so the skills have somewhere to keep living, and support is there if a top-up session is ever what you need.
Tom Walsh holds a PhD in cognitive-behavioural science from Oxford. He leads YouMindo's research partnerships and outcome measurement programs.